CSL delays spin-off, cuts profit outlook as US vaccination rates slide

CSL has announced a delay in its planned spin-off and has revised its profit outlook downward, citing a decline in US vaccination rates. This is significant as it reflects the ongoing challenges in the healthcare sector, particularly in vaccine distribution and public health initiatives. The company's decision could impact investor confidence and highlight the broader implications of vaccination hesitancy on pharmaceutical companies.